Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ: A Meta-Analysis and Diagnostic Test Accuracy Review

Version 1 : Received: 2 August 2023 / Approved: 3 August 2023 / Online: 3 August 2023 (10:03:19 CEST)

A peer-reviewed article of this Preprint also exists.

Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0. Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0.

Abstract

This study aimed to evaluate the diagnostic roles of various immunohistochemical markers in urothelial carcinoma in situ (uCIS) through a meta-analysis and review of diagnostic test accuracy. Immunohistochemical markers CK20, CD44, AMACR, and p53 were evaluated in the present study. We analyzed the expression rates of immunohistochemical markers and compared their diagnostic accuracies. The estimated expression rates were 0.803 (95% confidence interval [CI]: 0.726–0.862), 0.142 (95% CI: 0.033–0.449), 0.824 (95% CI: 0.720–0.895), and 0.600 (95% CI: 0.510–0.683) for CK20, CD44, AMACR, and p53, respectively. In the comparison between uCIS and reactive/normal urothelium, the expression of CK20, AMACR, and p53 in uCIS was significantly higher than in reactive/normal urothelium. CD44 showed significantly lower expression in uCIS than in the reactive/normal urothelium. Among the markers, AMACR had the highest sensitivity, specificity, and diagnostic odds ratio. The AUC on SROC was the highest for CK20. In conclusion, immunohistochemical markers, such as CK20, CD44, AMACR, and p53, can be useful in differentiating uCIS from reactive/normal urothelium.

Keywords

urothelial carcinoma in situ; immunohistochemistry; meta-analysis; diagnostic test accuracy review

Subject

Medicine and Pharmacology, Pathology and Pathobiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.